Cite
Untapped Potential of Poly(ADP-Ribose) Polymerase Inhibitors: Lessons Learned From the Real-World Clinical Homologous Recombination Repair Mutation Testing.
MLA
Lebedeva, Alexandra, et al. “Untapped Potential of Poly(ADP-Ribose) Polymerase Inhibitors: Lessons Learned From the Real-World Clinical Homologous Recombination Repair Mutation Testing.” World Journal of Oncology, vol. 15, no. 4, Aug. 2024, pp. 562–78. EBSCOhost, https://doi.org/10.14740/wjon1820.
APA
Lebedeva, A., Veselovsky, E., Kavun, A., Belova, E., Grigoreva, T., Orlov, P., Subbotovskaya, A., Shipunov, M., Mashkov, O., Bilalov, F., Shatalov, P., Kaprin, A., Shegai, P., Diuzhev, Z., Migiaev, O., Vytnova, N., Mileyko, V., & Ivanov, M. (2024). Untapped Potential of Poly(ADP-Ribose) Polymerase Inhibitors: Lessons Learned From the Real-World Clinical Homologous Recombination Repair Mutation Testing. World Journal of Oncology, 15(4), 562–578. https://doi.org/10.14740/wjon1820
Chicago
Lebedeva, Alexandra, Egor Veselovsky, Alexandra Kavun, Ekaterina Belova, Tatiana Grigoreva, Pavel Orlov, Anna Subbotovskaya, et al. 2024. “Untapped Potential of Poly(ADP-Ribose) Polymerase Inhibitors: Lessons Learned From the Real-World Clinical Homologous Recombination Repair Mutation Testing.” World Journal of Oncology 15 (4): 562–78. doi:10.14740/wjon1820.